Artelo Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

EQUITY (Detail Narrative 1)

EQUITY (Detail Narrative 1)					1 Months Ended	12 Months Ended
EQUITY (Detail Narrative 1)	Oct. 14, 2020 shares	Oct. 09, 2020 shares	Dec. 06, 2019 USD ($) $ / shares shares	Dec. 02, 2019 shares	Jun. 25, 2019 integer $ / shares shares	Aug. 31, 2021 USD ($) $ / shares shares	Aug. 31, 2020 USD ($) $ / shares shares	Aug. 31, 2019 USD ($) $ / shares shares	Dec. 03, 2020 $ / shares
Number of units sold					1,300,813,000
Value for issuance of common shares \| $						$ 8,103,000	$ 1,978,000	$ 8,376,379,000
Number of shares granted during period						2,755,100,000	74,000,000	184,000,000
Exercise price of warrants \| $ / shares					$ 6.4575
Derivative liability \| $							$ 0	$ 29,501,000
Intrinsic value \| $							$ 0	$ 0
Number of warrant purchase \| integer					1
Common stock, par value (in dollars per share) \| $ / shares					$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Represents as a common class A and B purchase warrant.
Exercise price of warrants \| $ / shares							$ 16.00
Represents as a common class A and B purchase warrant. \| Stock purchase agreement.
Warrant intrinsic value \| $							$ 0
Minimum [Member] \| Represents as a common class A and B purchase warrant. \| Stock purchase agreement.
Exercise price of warrants \| $ / shares							$ 8.00
Maximum [Member] \| Represents as a common class A and B purchase warrant. \| Stock purchase agreement.
Exercise price of warrants \| $ / shares							$ 14.00
Represents as a equity incentive plan. \| Director [Member]
Number of shares granted during period			10,000,000	22,250,000
Intrinsic value \| $			$ 24,401,000
Expiration date under plan			Dec. 06, 2029
Exercise price \| $ / shares			$ 2.65
Information about equity incentive plan. \| Director [Member]
Number of shares granted during period			40,000,000
Intrinsic value \| $			$ 97,606,000
Expiration date under plan			Dec. 06, 2029
Exercise price \| $ / shares			$ 2.65
Information of NEOMED Institute Canadian not-for-profit corporation.
Number of units sold								72,660,000
Value for issuance of common shares \| $								$ 539,417,000
Number of issuance of common shares								61,297,000
Shares issued for settlement of accrued liability								11,363,000
Value for shares issued for settlement of accrued liability \| $								$ 100,000,000
Over-Allotment Option [Member]
Number of units sold					191,102,000
Exercise price of warrants \| $ / shares					$ 6.765
Number of warrant purchase \| integer					104,065
Terms of common stock warrant					3 years
Number of purchase common stock shares					191,102,000
Percentage Of Underwriting Discounts And Commissions					0.08%
Offering price, per unit \| $ / shares					$ 6.15
Over-Allotment Option [Member] \| Ladenburg Thalmann [Member] \| Underwriting Agreement [Member]
Number of units sold	1,320,000,000
Number of issuance of common shares		1,320,000,000